Nature Communications (Mar 2024)

Expression of ALS-PFN1 impairs vesicular degradation in iPSC-derived microglia

  • Salome Funes,
  • Jonathan Jung,
  • Del Hayden Gadd,
  • Michelle Mosqueda,
  • Jianjun Zhong,
  • Shankaracharya,
  • Matthew Unger,
  • Karly Stallworth,
  • Debra Cameron,
  • Melissa S. Rotunno,
  • Pepper Dawes,
  • Megan Fowler-Magaw,
  • Pamela J. Keagle,
  • Justin A. McDonough,
  • Sivakumar Boopathy,
  • Miguel Sena-Esteves,
  • Jeffrey A. Nickerson,
  • Cathleen Lutz,
  • William C. Skarnes,
  • Elaine T. Lim,
  • Dorothy P. Schafer,
  • Francesca Massi,
  • John E. Landers,
  • Daryl A. Bosco

DOI
https://doi.org/10.1038/s41467-024-46695-w
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 25

Abstract

Read online

Abstract Microglia play a pivotal role in neurodegenerative disease pathogenesis, but the mechanisms underlying microglia dysfunction and toxicity remain to be elucidated. To investigate the effect of neurodegenerative disease-linked genes on the intrinsic properties of microglia, we studied microglia-like cells derived from human induced pluripotent stem cells (iPSCs), termed iMGs, harboring mutations in profilin-1 (PFN1) that are causative for amyotrophic lateral sclerosis (ALS). ALS-PFN1 iMGs exhibited evidence of lipid dysmetabolism, autophagy dysregulation and deficient phagocytosis, a canonical microglia function. Mutant PFN1 also displayed enhanced binding affinity for PI3P, a critical signaling molecule involved in autophagic and endocytic processing. Our cumulative data implicate a gain-of-toxic function for mutant PFN1 within the autophagic and endo-lysosomal pathways, as administration of rapamycin rescued phagocytic dysfunction in ALS-PFN1 iMGs. These outcomes demonstrate the utility of iMGs for neurodegenerative disease research and implicate microglial vesicular degradation pathways in the pathogenesis of these disorders.